Methodological standards for cost-of-illness studies using breast cancer, prostate cancer and colon cancer as an example;Methodische Standards von Krankheitskostenstudien am Beispiel von Brust-, Prostata- Und Darmkrebs

Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen

Volumn 103, Issue 6, 2009, Pages 305-318

  Damm, Oliver ^a   Hodek, Jan Marc ^a   Greiner, Wolfgang ^a  

^a BIELEFELD UNIVERSITY   (Germany)

Author keywords

Bowel cancer; Breast cancer; Cost of illness; Health economics; Prostate cancer

Indexed keywords

EID: 70350345495     PISSN: 18659217     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.zefq.2009.02.019     Document Type: Article

References (29)

1. Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. und das RKI. Krebs in Deutschland. 5. überarbeitete, aktualisierte Ausgabe. Saarbrücken: 2006.
2. Hodgson TA. Costs of illness in cost-effectiveness analysis. Pharmacoeconomics 1994;6:536-552
3. Greiner W. Die Berechnung von Kosten und Nutzen. In: Schöffski O, Schulenburg JM, Graf vd, Herausgeber. Gesundheitsökonomische Evaluationen. Dritte, vollständig überarbeitete Auflage. Berlin: Springer; 2007. S. 49-63.
4. Schulenburg JM, Graf vd, Greiner W. Gesundheitsökonomik. 2. Auflage. Tübingen: Mohr Siebeck; 2007.
5. Drummond M. Cost-of-illness studies. A major headache? Pharmacoeconomics 1992; 2:1-4.
6. Schöffski O. Grundformen gesundheitsökonomischer Evaluationen. In: Schöffski O, Schulenburg JM, Graf VD, Herausgeber. Gesundheitsö konomische Evaluationen. Dritte, vollständig überarbeitete Auflage. Berlin: Springer; 2007. S. 65-94.
7. Tarricone R. Cost-of-illness analysis. What room in health economics? Health Policy 2006;77:51-63.
8. Statistisches Bundesamt. Krankheitskosten 2004 und 2006. Wiesbaden: Statistisches Bundesamt; 2008.
9. Berkowitz N, Gupta S, Silberman G. Estimates of the lifetime direct costs of treatment for metastatic breast cancer. In Value in Health 2000;3:23-30.
10. [10] Karnon J, Kerr GR, Jack W, Papo NL, Cameron DA. Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis. British Journal of Cancer 2007;97: 479-485 (Pubitemid 47258450)
11. [11] Lidgren M, Wilking N, Jönsson B, Rehnberg C. Resource use and costs associated with different states of breast cancer. International Journal of Technology Assessment in Health Care 2007;23:223-231 (Pubitemid 46642729)
12. Lidgren M, Wilking N, Jönnson B. Cost of breast cancer in Sweden in 2002. European Journal of Health Economics 2007;8: 5-15.
13. [13] Oliva J, Lobo F, Lopez-Bastida J, Zozaya N, Romay R. Indirect costs of cervical cancer and breast cancer in Spain. Eur J Health Econ 2005;6:309-313 (Pubitemid 41779929)
14. [14] Wai ES, Trevisan CH, Taylor CM, Mates D, Jackson JS, Olivotto IA. Health system costs of metastatic breast cancer. Breast Cancer Research and Treatment 2001;65:233-240 (Pubitemid 32328544)
15. [15] Will BP, Berthelot JM, Le Petit C, Tomiak EM, Verma S, Evans WK. Estimates of the lifetime costs of breast cancer treatment in Canada. European Journal of Cancer 2000;36:724-735 (Pubitemid 30179743)
16. [16] Graver SA, Coupai L, Zowall H, Rajan R, Trachtenberg J, Elhilali M, et al. The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model. Canadian Medical Association Journal 2000;162:987-992 (Pubitemid 30207497)
17. Max W, Rice DP, Sung HY, Michel M, Breuer W, Zhang X. The economic burden of prostate cancer, California, 1998. Cancer 2002;94:2906-2913
18. Norlund A, Alvegard T, Lithman T, Merlo J, Noreen D. Prostate Cancer. Prevalencebased healthcare costs. Scandinavian journal of urology and nephrology 2003;37: 371-375
19. [19] Piper NY, Kusada L, Lance R, Foley J, Moul J, Seay T. Adenocarcinoma of the prostate: an expensive way to die. Prostate Cancer and Prostatic Diseases 2002;5: 164-166 (Pubitemid 34777902)
20. Sangar VK, Ragavan N, Matanhelia SS, Watson ME, Blades RA. The economic consequences of prostate and bladder cancer in the UK. BJU International 2005;95: 59-63.
21. [21] Bouvier V, Reaud JM, Gignoux M, Launoy G. Cost of diagnostic and therapeutic management of colorectal cancer according to stage at diagnosis in the Calvados Department, France. Eur J Health Econ 2003;4:102-106 (Pubitemid 36841519)
22. Clerc L, Jooste V, Lejeune C, Schmitt B, Arveux P, Quantin C, et al. Cost of care of colorectal cancers according to health care patterns and stage at diagnosis in France. Eur J Health Econ 2007, online first.
23. [23] Maroun J, Ng E, Berthelot JM, Le Petit C, Dahrouge S, Flanagan WM, et al. Lifetime costs of colon and rectal cancer management in Canada. Chronic Diseases in Canada 2003;24:91-101. (Pubitemid 38155547)
24. Paramore LC, Thomas SK, Knopf KB, Cragin LS, Fraeman KH. Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer. Clinical Colorectal Cancer 2006;6:52-58
25. Selke B, Marissal JP, Chevallier D, Lebrun T. Cost of colorectal cancer in France in 1999. Gastroentérologie clinique et biologique 2003;27:22-27
26. Yabroff KR, Mariotto AB, Feuer E, Brown ML. Projections of the costs associated with colorectal cancer care in the united states, 2000-2020. Health Economics 2007, online first.
27. [27] Polder JJ, Meerding WJ, Bonneux L, van der Maas PJ. A cross-national perspective on cost of illness: a comparison of studies from The Netherlands, Australia, Canada, Germany, United Kingdom, and Sweden. Eur J Health Econ 2005;6(3):223-232 (Pubitemid 41638845)
28. Finkelstein E, Corso P. Cost-of-illness analysis for policy making: a cautionary tale of use and misuse. Expert Review of Pharmacoeconomics & Outcomes Research 2003; 3:367-369
29. [29] Clabaugh G, Ward MM. Cost-of-Illness studies in the United States: a systematic review of methodologies used for direct costs. Value in Health 2008;1:13-21. (Pubitemid 351160872)